South San Francisco, Calif.
Founded: 1999

Why It's Fierce: Fluidigm is one of two nanotechnology companies in the Fierce 15. With volumes of Human Genome data waiting to be thoroughly analyzed, scientists need new tools to perform more tests with greater precision. Fluidigm's microfluidics product is designed specifically for this large and growing market. A syndicate of blue chip investors lead by Lehman Brothers Healthcare Fund, Euclid SR Partners, InterWest Partners, Versant Ventures and Lilly BioVentures are betting the company can convert the concept into a viable product.

What to look for in 2003: Fluidigm may announce its first reference customers in 2003.


Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i